Biomea Fusion, Inc., a clinical-stage diabetes and obesity medicines company, focuses on the discovery and development of oral drugs to treat patients with diabetes and obesity. It's lead clinical program's drug candidates are COVALENT-111 ...
Q1 2026
May 11, 2026
FY 2025
Mar 24, 2026
Q4 2025
Q3 2025
Nov 4, 2025
Q2 2025
Aug 5, 2025